

# Contents

---

Preface .....	v
Contributors .....	xi
Color Plates .....	xv

## **PART I: TRENDS IN PROSTATE CANCER SCREENING**

1 Overview of US Prostate Cancer Trends in the Era of PSA Screening .....	3
<i>Ruth Etzioni, Roman Gulati, and Angela Mariotto</i>	
2 Trends in Prostate Cancer Screening: Overview of the UK .....	15
<i>Richard J. Bryant and Freddie C. Hamdy</i>	
3 Trends in Prostate Cancer Screening: Canada .....	23
<i>Robert K. Nam and Laurence H. Klotz</i>	
4 Trends in Prostate Cancer Screening – Overview of Europe .....	35
<i>Sanjai K. Addla and Bob Djavan</i>	

## **PART II: PROSTATE-SPECIFIC ANTIGEN**

5 Evolution of Prostate-Specific Antigen for Screening .....	51
<i>Javier Hernandez and Edith Canby-Hagino</i>	
6 The Performance Characteristics of Prostate-Specific Antigen for Prostate Cancer Screening .....	61
<i>Ian M. Thompson, Jr. and Donna P. Ankerst</i>	
7 The Performance of PSA for Predicting Prostate Cancer After a Prior Negative Prostate Biopsy .....	71
<i>Catherine M. Tangen</i>	
8 Subfractions and Derivatives of Total Prostate-Specific Antigen in the Early Detection of Prostate Cancer .....	79
<i>Alexander Haese and Alan W. Partin</i>	
9 PSA Velocity at Presentation as a Predictor of Prostate Cancer Aggressiveness .....	97
<i>Jason A. Efsthathiou and Anthony V. D’Amico</i>	

## **PART III: RISK ASSESSMENT FOR PROSTATE CANCER**

10 Nomograms for Prostate Cancer .....	117
<i>Shahrokh F. Shariat and Michael W. Kattan</i>	

11	Decision Aid Criteria and Artificial Neural Networks for Optimizing Prostate Cancer Risk Prediction . . . . .	181
	<i>Felix K.-H. Chun and Pierre I. Karakiewicz</i>	
12	Development of the Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator . . . . .	195
	<i>Donna P. Ankerst and Ian M. Thompson</i>	
13	Integration of Risk Assessment in Prostate Cancer Screening . . . . .	205
	<i>Kadee E Thompson, Amanda Reed, and Dipen J Parekh</i>	
14	Family History of Prostate Cancer During Rapidly Increasing Incidence . . . . .	213
	<i>Kari Hemminki and Justo Lorenzo Bermejo</i>	

#### **PART IV: RECENT BIOMARKERS FOR PROSTATE CANCER**

15	PSA Isoforms: [−2]proPSA Significant Adjunct to Free PSA . . . . .	225
	<i>Jeffrey E. Tam</i>	
16	PCA3 . . . . .	233
	<i>Jack Groskopf, Jack Schalken, and Harry Rittenhouse</i>	
17	Transcriptional Profiling of Prostate Cancer: Biomarker Identification and Clinical Applications . . . . .	243
	<i>Nigel Clegg and Peter S. Nelson</i>	
18	Biomarkers for Prostate Cancer Detection: Family-Based Linkage Analysis and Case–Control Association Studies . . . . .	261
	<i>Joke Beuten and Teresa L Johnson-Pais</i>	
19	<i>GSTP1</i> Hypermethylation for Prostate Cancer Detection . . . . .	279
	<i>Rui Henrique and Carmen Jerónimo</i>	
20	EPCA and EPCA-2 as Potential Biomarkers for Prostate Cancer Detection . . . . .	289
	<i>Eddy S. Leman and Robert H. Getzenberg</i>	

#### **PART V: DESIGN AND METHODOLOGIC CONSIDERATIONS IN BIOMARKER STUDIES**

21	Toward a Robust System for Biomarker Triage and Validation – EDRN Experience . . . . .	297
	<i>Ziding Feng, Jacob Kagan and Sudhir Srivastava</i>	
22	Statistical Evaluation of Markers and Risk Tools for Prostate Cancer Classification and Prediction . . . . .	307
	<i>Yingye Zheng and Donna P. Ankerst</i>	
23	Pitfalls in Prostate Cancer Biomarker Evaluation Studies . . . . .	319
	<i>Donna P. Ankerst</i>	

#### **PART VI: BUILDING UPON RECENTLY COMPLETED AND ONGOING PROSPECTIVE TRIALS**

24	Prostate-Specific Antigen and Its Role on the Prostate Cancer Prevention Trial . . . . .	333
	<i>Catherine M. Tangen and Phyllis J. Goodman</i>	

---

25	The Selenium and Vitamin E Cancer Prevention Trial . . . . .	349
	<i>Eric A. Klein</i>	
26	PLCO: A Randomized Controlled Screening Trial for Prostate, Lung, Colorectal, and Ovarian Cancer . . . . .	361
	<i>Amanda Black, Robert L. Grubb III, and E. David Crawford</i>	
27	The European Randomized Study of Screening for Prostate Cancer (ERSPC) . . . . .	373
	<i>Tineke Wolters and Fritz H. Schröder</i>	
	Index . . . . .	387



<http://www.springer.com/978-1-60327-280-3>

Prostate Cancer Screening

Second Edition

Pauler Ankerst, D.; Tangen, C.M.; Thompson, I.M. (Eds.)

2009, XVI, 397 p., Hardcover

ISBN: 978-1-60327-280-3

A product of Humana Press